The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Baseline Metabolic Tumor Volume Predicts Outcome in High–Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies
Open accessAbstract
Purpose: Identifying patients at high risk of progression and early death among those with high-tumor-burden follicular lymphoma (FL) is unsatisfactory with current prognostic models. This study aimed to determine the prognostic impact of the total metabolic tumor volume (TMTV) measured at baseline with [18 F]fluorodeoxyglucose/positron emission tomography-computed tomography ([18 F]FDG/PET-CT) scans and its added value to these models. Patients and Methods: A pooled analysis was performed by using patient data and centrally reviewed baseline PET-CT scans for 185 patients with FL who were receiving immunochemotherapy within three prospective trials. TMTV was computed by using the 41% maximum standardized uptake value thresholding method, and the optimal cutoff for survival prediction was determined. Results: Median age was 55 years, 92% of patients had stage III to IV disease, 37% had a Follicular Lymphoma International Prognostic Index (FLIPI) score of 3 to 5, and 31% had a FLIPI2 score of 3 to 5. With a median follow-up of 64 months, overall 5-year progression-free survival (PFS) was 55% and overall survival (OS) was 92%. Median TMTV was 297 cm 3 (quartile 1 through quartile 3, 135 to 567 cm 3). The optimal cutoff identified was 510 cm 3, with a markedly inferior survival in the 29% of patients with TMTV > 510 cm 3. Five-year PFS was 33% versus 65% (hazard ratio [HR], 2.90; P < .001), and 5-year OS was 85% versus 95% (HR, 3.45; P = .010). On multivariable analysis, TMTV (HR, 2.3; P = .002) and FLIPI2 score (HR, 2.2; P = .002) were independent predictors of PFS. In combination, they identify three risk groups: high TMTV and intermediate-to-high FLIPI2 score with 5-year PFS of 20% (HR, 5.0; P < .001), high TMTV or intermediate-to-high FLIPI2 score with 5-year PFS of 46% (HR, 2.1; P = .007), and low TMTV and low FLIP2 with 5-year PFS of 69%. Conclusion: Baseline TMTV is a strong independent predictor of outcome in FL. In combination with FLIPI2 score, it identifies patients at high risk of early progression. It warrants further validation as a biomarker for development of first-line PET-adapted approaches in FL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Revised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Self-citationCamp, R. L., Dolled-Filhart, M., & Rimm, D. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0713 · Cited by 3,744
Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001
Morton, L. M., Wang, S. S., Devesa, S. S., Hartge, P., Weisenburger, D. D., & Linet, M. S. (2006) · Blood · doi:10.1182/blood-2005-06-2508 · Cited by 1,683
Barrington, S. F., Mikhaeel, N. G., Kostakoglu, L., Meignan, M., Hutchings, M., Müeller, S. P., Schwartz, L. H., Zucca, E., Fisher, R. I., Trotman, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.5229 · Cited by 1,665
Self-citationPartial-Volume Effect in PET Tumor Imaging
Soret, M., Bacharach, S. L., & Buvat, I. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.035774 · Cited by 1,549
Follicular lymphoma international prognostic index
Solal-Celigny, P. (2006) · Current Treatment Options in Oncology · doi:10.1007/s11864-006-0036-3 · Cited by 1,339
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
Boellaard, R., O’Doherty, M. J., Weber, W. A., Mottaghy, F. M., Lonsdale, M. N., Stroobants, S. G., Oyen, W. J. G., Kotzerke, J., Hoekstra, O. S., Pruim, J., et al. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1297-4 · Cited by 1,326
Armitage, J. O., & Weisenburger, D. D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2780 · Cited by 1,251
Salles, G., Seymour, J. F., Offner, F., López-Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J. V., Brice, P., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62175-7 · Cited by 1,079
Self-citationMarcus, R. (2005) · Blood · doi:10.1182/blood-2004-08-3175 · Cited by 967
Casulo, C., Byrtek, M., Dawson, K. L., Zhou, X., Farber, C. M., Flowers, C. R., Hainsworth, J. D., Maurer, M. J., Cerhan, J. R., Link, B. K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7534 · Cited by 850
Federico, M., Bellei, M., Marcheselli, L., Luminari, S., Lopez-Guillermo, A., Vitolo, U., Pro, B., Pileri, S., Pulsoni, A., Soubeyran, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3991 · Cited by 751
Self-citationFollicular Lymphoma International Prognostic Index
Solal-Celigny, P. (2004) · Blood · doi:10.1182/blood-2003-12-4434 · Cited by 626
Pastore, A., Jurinovic, V., Kridel, R., Hoster, E., Staiger, A. M., Szczepanowski, M., Pott, C., Kopp, N., Murakami, M., Horn, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00169-2 · Cited by 618
Marcus, R., Imrie, K., Solal-Celigny, P., Catalano, J. V., Dmoszynska, A., Raposo, J. C., Offner, F. C., Gomez-Codina, J., Belch, A., Cunningham, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5376 · Cited by 594
Smith, A., Crouch, S., Lax, S., Li, J., Painter, D., Howell, D., Patmore, R., Jack, A., & Roman, E. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.94 · Cited by 424
Mikhaeel, N. G., Smith, D., Dunn, J. T., Phillips, M., Møller, H., Fields, P. A., Wrench, D., & Barrington, S. F. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3315-7 · Cited by 295
Federico, M., Luminari, S., Dondi, A., Tucci, A., Vitolo, U., Rigacci, L., Di Raimondo, F., Carella, A. M., Pulsoni, A., Merli, F., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.0866 · Cited by 264
Self-citationTan, D. C. L., Horning, S. J., Hoppe, R. T., Levy, R., Rosenberg, S. A., Sigal, B. M., Warnke, R. A., Natkunam, Y., Han, S. S., Yuen, A. R., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491514 · Cited by 262
Sasanelli, M., Meignan, M., Haioun, C., Berriolo-Riedinger, A., Casasnovas, R.-O., Biggi, A., Gallamini, A., Siegel, B. A., Cashen, A. F., Véra, P., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2822-7 · Cited by 240
Self-citationDupuis, J., Berriolo-Riedinger, A., Julian, A., Brice, P., Tychyj-Pinel, C., Tilly, H., Mounier, N., Gallamini, A., Feugier, P., Soubeyran, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.0934 · Cited by 191
Self-citationCottereau, A.-S., Lanic, H., Mareschal, S., Meignan, M., Vera, P., Tilly, H., Jardin, F., & Becker, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2825 · Cited by 188
Self-citationMeignan, M., Sasanelli, M., Casasnovas, R. O., Luminari, S., Fioroni, F., Coriani, C., Masset, H., Itti, E., Gobbi, P. G., Merli, F., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2705-y · Cited by 186
Self-citationTrotman, J., Luminari, S., Boussetta, S., Versari, A., Dupuis, J., Tychyj, C., Marcheselli, L., Berriolo-Riedinger, A., Franceschetto, A., Julian, A., et al. (2014) · The Lancet Haematology · doi:10.1016/s2352-3026(14)70008-0 · Cited by 182
Self-citationBaseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma
Kanoun, S., Rossi, C., Berriolo-Riedinger, A., Dygai-Cochet, I., Cochet, A., Humbert, O., Toubeau, M., Ferrant, E., Brunotte, F., & Casasnovas, R.-O. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2783-x · Cited by 180
Self-citationCeriani, L., Martelli, M., Zinzani, P. L., Ferreri, A. J. M., Botto, B., Stelitano, C., Gotti, M., Cabras, M. G., Rigacci, L., Gargantini, L., et al. (2015) · Blood · doi:10.1182/blood-2014-12-616474 · Cited by 178
Self-citationKanoun, S., Tal, I., Berriolo-Riedinger, A., Rossi, C., Riedinger, J., Vrigneaud, J., Legrand, L., Humbert, O., Casasnovas, O., Brunotte, F., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140830 · Cited by 113
Cottereau, A., Becker, S., Broussais, F., Casasnovas, O., Kanoun, S., Roques, M., Charrier, N., Bertrand, S., Delarue, R., Bonnet, C., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw011 · Cited by 113
Self-citationQuak, E., Le Roux, P.-Y., Hofman, M. S., Robin, P., Bourhis, D., Callahan, J., Binns, D., Desmonts, C., Salaun, P.-Y., Hicks, R. J., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3128-0 · Cited by 107
Cottereau, A.-S., Hapdey, S., Chartier, L., Modzelewski, R., Casasnovas, O., Itti, E., Tilly, H., Vera, P., Meignan, M. A., & Becker, S. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.180406 · Cited by 64
Self-citationCasulo, C., Day, B., Dawson, K. L., Zhou, X., Flowers, C. R., Farber, C. M., Hainsworth, J. D., Cerhan, J. R., Link, B. K., Zelenetz, A. D., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv375 · Cited by 30
Quak, E., Hovhannisyan, N., Lasnon, C., Fruchart, C., Vilque, J., Musafiri, D., & Aide, N. (2014) · Haematologica · doi:10.3324/haematol.2014.104125 · Cited by 25
Baseline metabolic tumour volume in Hodgkin lymphoma: the prognostic value of accessory cells
Meignan, M. A. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2815-6 · Cited by 16
Self-citation
Cited by
Vercellino, L., Di Blasi, R., Kanoun, S., Tessoulin, B., Rossi, C., D'Aveni-Piney, M., Obéric, L., Bodet-Milin, C., Bories, P., Olivier, P., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003001 · Cited by 410
Self-citationA Guide to ComBat Harmonization of Imaging Biomarkers in Multicenter Studies
Orlhac, F., Eertink, J. J., Cottereau, A.-S., Zijlstra, J. M., Thieblemont, C., Meignan, M., Boellaard, R., & Buvat, I. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262464 · Cited by 348
Self-citationCottereau, A.-S., Hapdey, S., Chartier, L., Modzelewski, R., Casasnovas, O., Itti, E., Tilly, H., Vera, P., Meignan, M. A., & Becker, S. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.180406 · Cited by 64
Self-citation
Metadata
- Authors
- Meignan, M., Cottereau, A. S., Versari, A., Chartier, L., Dupuis, J., Boussetta, S., Grassi, I., Casasnovas, R.-O., Haioun, C., Tilly, H., Tarantino, V., Dubreuil, J., Federico, M., Salles, G., Luminari, S., & Trotman, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-10-20
- Volume
- 34
- Issue
- 30
- Pages
- 3618-3626
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2507512417
- Cited by
- 326
- References
- 34
- FWCI
- 23.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.